Type V Collagen Fragments for COPD and Asthma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic obstructive pulmonary disease (COPD) and asthma are limited by their effectiveness and often come with undesirable side effects, and early detection and diagnosis of COPD are challenging due to its progressive nature and overlapping symptoms with other respiratory conditions.
Innovation Solution
Administration of type V collagen or tolerogenic fragments thereof, either orally, intravenously, by intrapulmonary instillation, inhalation, or intramuscularly, as a therapeutically effective amount, potentially combined with bronchodilators or corticosteroids, to treat COPD and asthma, and for preventing disease progression, along with methods for diagnosing and monitoring using collagen V-specific antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for COPD and asthma are used, then disease symptoms can be managed, but side effects increase and treatment effectiveness is limited
Solution Approach 1:
The patent changes the fundamental parameter of treatment approach by shifting from conventional symptom management (bronchodilators, corticosteroids) to immunomodulation through type V collagen administration. This parameter change aims to address the underlying immune dysregulation in COPD and asthma, potentially improving treatment effectiveness while reducing side effects associated with current therapies
2Loss of time
If early detection methods for COPD are implemented, then treatment timing can be improved, but diagnostic difficulty increases due to progressive nature and overlapping symptoms
Solution Approach 1:
The patent introduces type V collagen-specific antibodies as an intermediary marker for early detection and monitoring of COPD and asthma. These antibodies serve as a measurable indicator that can detect disease presence and progression before severe symptoms manifest, overcoming the diagnostic difficulty caused by overlapping symptoms and progressive disease nature
Data Source
AI summary
The present invention provides compounds and methods for treating or preventing pulmonary diseases include COPD and asthma. In particular, the present invention provides for compounds comprising type V collagen, or tolerizing fragments thereof, for the treatment of COPD and asthma.